Catalyst Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
182
- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
3
Catalyst Pharmaceuticals General Information
Description
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Contact Information
Website
www.catalystpharma.com(Operating Subsidiary)
Corporate Office
- 355 Alhambra Circle
- Suite 801
- Coral Gables, FL 33134
- United States
Corporate Office
- 355 Alhambra Circle
- Suite 801
- Coral Gables, FL 33134
- United States
Catalyst Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Catalyst Pharmaceuticals Comparisons
Industry
Financing
Details
Catalyst Pharmaceuticals Competitors (78)
One of Catalyst Pharmaceuticals’s 78 competitors is ACADIA Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Xeris Biopharma Holdings | Formerly VC-backed | Chicago, IL | ||||
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Novartis | Corporation | Basel, Switzerland |
Catalyst Pharmaceuticals Patents
Catalyst Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026035689-A1 | Vamorolone solid oral dosage forms | Pending | 06-Aug-2024 | ||
| EP-4387620-A1 | Method for treating botulinum toxin poisoning | Pending | 19-Aug-2021 | ||
| EP-4387620-A4 | Method for treating botulinum toxin poisoning | Pending | 19-Aug-2021 | ||
| US-20230074200-A1 | Method for treating botulinum toxin poisoning | Pending | 19-Aug-2021 | ||
| WO-2023023463-A1 | Method for treating botulinum toxin poisoning | Inactive | 19-Aug-2021 | A61K31/44 |
Catalyst Pharmaceuticals Signals
Catalyst Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Catalyst Pharmaceuticals Investments & Acquisitions (3)
Catalyst Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Santhera Pharmaceuticals (Vamorolone License Located in Pratteln, Switzerland) for . The deal was made on 19-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Santhera Pharmaceuticals (Vamorolone License Located in Pratteln, Switzerland) | 19-Jul-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Santhera Pharmaceuticals Holding | 20-Jun-2023 | PIPE | Biotechnology | ||
| FYCOMPA | 24-Jan-2023 | Merger/Acquisition | Drug Discovery |
Catalyst Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| FYCOMPA |
Catalyst Pharmaceuticals FAQs
-
When was Catalyst Pharmaceuticals founded?
Catalyst Pharmaceuticals was founded in 2002.
-
Where is Catalyst Pharmaceuticals headquartered?
Catalyst Pharmaceuticals is headquartered in Coral Gables, FL.
-
What is the size of Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals has 182 total employees.
-
What industry is Catalyst Pharmaceuticals in?
Catalyst Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Catalyst Pharmaceuticals a private or public company?
Catalyst Pharmaceuticals is a Private company.
-
What is the current valuation of Catalyst Pharmaceuticals?
The current valuation of Catalyst Pharmaceuticals is .
-
What is Catalyst Pharmaceuticals’s current revenue?
The current revenue for Catalyst Pharmaceuticals is .
-
How much funding has Catalyst Pharmaceuticals raised over time?
Catalyst Pharmaceuticals has raised $222M.
-
Who are Catalyst Pharmaceuticals’s investors?
New Leaf Venture has invested in Catalyst Pharmaceuticals.
-
Who are Catalyst Pharmaceuticals’s competitors?
ACADIA Pharmaceuticals, Xeris Biopharma Holdings, Marinus Pharmaceuticals, BioMarin Pharmaceutical, and Novartis are some of the 78 competitors of Catalyst Pharmaceuticals.
-
When was Catalyst Pharmaceuticals acquired?
Catalyst Pharmaceuticals was acquired on 16-Jul-2026.
-
Who acquired Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals was acquired by Angelini Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process